COFCO Biotechnology Co., Ltd.

Total Valuation

COFCO Biotechnology Co., Ltd. carries a market capitalization of 8.35B, placing it among publicly traded companies globally. Its enterprise value stands at 14.35B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

COFCO Biotechnology Co., Ltd. currently has 1.86B shares outstanding.

Valuation Ratios

COFCO Biotechnology Co., Ltd. trades at a trailing price-to-earnings ratio of 99.49. The price-to-sales ratio is 1.00, and the price-to-book ratio stands at 3.86.

Enterprise Valuation

On an enterprise value basis, COFCO Biotechnology Co., Ltd. trades at an EV/EBITDA multiple of 47.79 and an EV/FCF ratio of 23.87. The EV/Sales ratio of 1.14 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 47.79 provides insight into valuation relative to core operating earnings.

Financial Position

COFCO Biotechnology Co., Ltd. maintains a current ratio of 1.17, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 29.94, indicating elevated leverage, while an interest coverage ratio of 5.21 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, COFCO Biotechnology Co., Ltd. has paid 11.60M in income taxes, reflecting an effective tax rate of 30.39.

Stock Price Statistics

COFCO Biotechnology Co., Ltd.'s stock has declined approximately -23.07692% over the past 52 weeks. The 50-day moving average sits at 5.22, while the 200-day moving average is 6.02.

Income Statement

Over the trailing twelve months, COFCO Biotechnology Co., Ltd. generated 12.56B in revenue and converted that into -95.55M in net income, yielding earnings per share of -0.05. EBITDA reached 300.32M, while operating income came in at 300.32M.

Balance Sheet

COFCO Biotechnology Co., Ltd. holds 1.82B in cash and equivalents against 3.23B in total debt, resulting in a net debt position of 1.20B. Total book value stands at 3.24B, with working capital of 1.02B providing operational flexibility.

Cash Flow

After subtracting -535.31M in capital expenditures, free cash flow totaled -535.31M - equivalent to -0.29 per share.

Margins

COFCO Biotechnology Co., Ltd. operates with a gross margin of 8.07, reflecting its pricing power and cost economics. The operating margin of 2.39 and net profit margin of -0.76 provide insight into operational efficiency.

Dividends & Yields

The company's payout ratio of -55.47 indicates the proportion of earnings distributed to shareholders.

Stock Splits

COFCO Biotechnology Co., Ltd.'s most recent stock split took place on December 7, 2005 with a 1:2 split ratio.

Scores

COFCO Biotechnology Co., Ltd. posts an Altman Z-Score of 2.10, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.